Who Owns Lifecore Biomedical Company?

Lifecore Biomedical Bundle

Get Full Bundle:

	5 FORCES	$15	$10
	BCG	$15	$10
	CANVAS	$15	$10
	4P's MIX	$15	$10
	PESTLE	$15	$10
	SWOT	$15	$10

TOTAL:

ADD TO CART

Who Owns Lifecore Biomedical?

Understanding Lifecore Biomedical's ownership is key to its strategic path. A major change occurred in November 2022 when Landec Corporation rebranded to Lifecore Biomedical, Inc. (LFCR), becoming a public entity again.

This move re-established the Minnesota-based company as a focused, publicly traded firm. Lifecore Biomedical, founded in 1965, is now a contract development and manufacturing organization specializing in fill/finish services and pharmaceutical-grade sodium hyaluronate.

As of August 2025, Lifecore Biomedical has a market capitalization of approximately $273.99 million. The company's journey includes its origins as American Medical Research, Inc. and its evolution into a key player in sterile injectable products. Its expertise extends to manufacturing products like Lifecore Biomedical PESTEL Analysis.

Lifecore Biomedical's journey began in 1965 when Dr. Otto Sartorius established American Medical Research, Inc. in Minneapolis, Minnesota. Initially, the company focused on microbial diagnostic devices.

Founding Vision

Dr. Otto Sartorius founded the company with a vision for medical research and diagnostics. This early focus laid the groundwork for future specialization in biomaterials.

Early Focus

The company's initial operations centered on microbial diagnostic devices. This specialization was a key aspect of its early business strategy.

Public Offering

An Initial Public Offering in 1968 marked a significant shift, changing the company's name to DIAGNOSTIC Inc. and broadening its ownership structure.

Strategic Pivot

The mid-1980s saw a rebranding to Lifecore Biomedical. This coincided with the crucial development of its sodium hyaluronate production.

FDA Approval

Lifecore Biomedical received its first FDA approval for a product utilizing its sodium hyaluronate in the mid-1980s. This was a major milestone for the company.

Ownership Details

Specific details regarding the equity split among founders or early angel investors from the company's inception are not publicly available. The 1968 IPO indicates a wider distribution of ownership.

The company's evolution from microbial diagnostics to a focus on biomaterials like sodium hyaluronate, beginning in 1981, was a strategic move that shaped its future trajectory. This shift was validated by its first FDA approval for a product incorporating its proprietary sodium hyaluronate. Understanding the Marketing Strategy of Lifecore Biomedical provides further context on how these early developments influenced its market positioning.

Early Ownership Landscape

While precise details of initial founder equity are not public, the 1968 IPO of DIAGNOSTIC Inc. signifies a transition to a broader ownership base. This event was a critical step in the company's early financial history.

• Founding: 1965 by Dr. Otto Sartorius
• Initial Name: American Medical Research, Inc.
• IPO Year: 1968
• Post-IPO Name: DIAGNOSTIC Inc.
• Key Product Development: Sodium hyaluronate (NaHy) production started in 1981
• Rebranding: Lifecore Biomedical in the mid-1980s

Lifecore Biomedical SWOT Analysis

• Complete SWOT Breakdown
• Fully Customizable
• Editable in Excel & Word
• Professional Formatting
• Investor-Ready Format

GET TEMPLATE ➔

Lifecore Biomedical's ownership has seen significant shifts, including a transition from public to private ownership and subsequent re-emergence as a standalone public entity. These changes have reshaped its corporate structure and strategic focus.

The corporate ownership structure of Lifecore Biomedical has evolved considerably, culminating in its current status as a publicly traded company. This evolution has been driven by strategic acquisitions and divestitures, ultimately positioning the company as a pure-play contract development and manufacturing organization (CDMO).

Key Stakeholders and Holdings

Institutional investors collectively hold a substantial stake in Lifecore Biomedical, indicating significant confidence from the financial community. These holdings have seen minor adjustments in early 2025.

• Institutional investors collectively own 66.85% as of January 2025.
• Mutual funds increased their stake to 18.66% in January 2025.
• Insiders increased their holdings to 3.47% in January 2025.
• Individual investors held approximately 35% as of November 2024.

Major institutional shareholders play a crucial role in Lifecore Biomedical's corporate ownership structure. These include prominent firms such as Wynnefield Capital Inc, Legion Partners Asset Management, LLC, Greenhaven Road Investment Management, L.P., BlackRock, Inc., and Vanguard Group Inc. For example, Wynnefield Capital Inc. beneficially owned approximately 16.0% of the Issuer's outstanding voting securities as of June 2024. These significant shareholding patterns directly influence the company's strategic direction, particularly its investments in expanding contract development and manufacturing capabilities and hyaluronic acid production, aligning with its Mission, Vision & Core Values of Lifecore Biomedical.

Lifecore Biomedical PESTLE Analysis

• Covers All 6 PESTLE Categories
• No Research Needed – Save Hours of Work
• Built by Experts, Trusted by Consultants
• Instant Download, Ready to Use
• 100% Editable, Fully Customizable

GET TEMPLATE ➔

The Board of Directors at Lifecore Biomedical, Inc. is composed of individuals who bring a mix of executive leadership and independent financial expertise. As of August 2025, the board includes Paul Josephs, who serves as President, CEO, and Director. Other key members include Katrina Houde as Independent Chairman of the Board, and directors Nelson Obus, Joshua Schechter, Humberto Antunes, Christopher Kiper, Paul Johnson, Jason Aryeh, and Matthew Korenberg.

Voting power within Lifecore Biomedical is primarily held by common stockholders, with each share typically granting one vote. However, the Series A Preferred Stockholders possess distinct voting rights. As of February 2025, these preferred stockholders held approximately 11,772,069 shares of common stock on an as-converted basis, accounting for about 31.79% of the voting power on specific proposals. They also have the right to nominate two directors to the board, voting separately for their nominees and jointly with common stockholders for others. A significant governance update occurred in August 2024 when shareholders approved the phased declassification of the Board, ensuring all directors will be subject to annual reelection by the 2025 Annual Meeting, thereby increasing shareholder accountability and aligning with effective Growth Strategy of Lifecore Biomedical.

Key Voting Power Dynamics

Understanding the voting structure is crucial for Lifecore Biomedical ownership. The Series A Preferred Stockholders hold substantial voting influence, impacting director nominations and key proposals.

• Common stockholders have one vote per share.
• Series A Preferred Stockholders can nominate two directors.
• As of February 2025, Series A Preferred Stock represented 31.79% of voting power on certain proposals.
• Board declassification by 2025 enhances director accountability.

Lifecore Biomedical Business Model Canvas

• Complete 9-Block Business Model Canvas
• Effortlessly Communicate Your Business Strategy
• Investor-Ready BMC Format
• 100% Editable and Customizable
• Clear and Structured Layout

GET TEMPLATE ➔

Lifecore Biomedical has seen significant shifts in its corporate structure and ownership dynamics over the past few years. These changes are designed to enhance governance and provide strategic flexibility for growth, reflecting broader industry trends towards specialized contract development and manufacturing organizations (CDMOs).

The company's strategic direction emphasizes its role as a pure-play CDMO, aligning with increasing institutional interest in specialized service providers. These developments are crucial for understanding Lifecore Biomedical ownership and its evolving corporate structure.

Ownership Structure Evolution

Recent share authorization increases and insider transactions provide insights into Lifecore Biomedical's ownership trends. These movements are key indicators for potential Lifecore Biomedical investors.

Strategic Capacity Expansion

The installation of new filling equipment significantly boosts Lifecore Biomedical's operational capacity. This expansion supports its Target Market of Lifecore Biomedical and revenue growth potential.

Leadership and Governance

New leadership and governance adjustments, including board declassification, aim to strengthen the company's framework. Understanding who owns Lifecore Biomedical is also tied to its management structure.

Financial Reporting Scrutiny

Disclosed material weaknesses in financial reporting highlight areas for improvement. This is a critical factor for Lifecore Biomedical company stakeholders and potential Lifecore Biomedical acquisition interest.

Lifecore Biomedical Porter's Five Forces Analysis

• Covers All 5 Competitive Forces in Detail
• Structured for Consultants, Students, and Founders
• 100% Editable in Microsoft Word & Excel
• Instant Digital Download – Use Immediately
• Compatible with Mac & PC – Fully Unlocked

GET TEMPLATE ➔